勘误：一种改进的酶联聚焦形成试验揭示巴洛沙韦酸是一种抗汉坦病毒感染的潜在抗病毒治疗药物。
Corrigendum: An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection.
作者信息
Ye Chuantao, Wang Dan, Liu He, Ma Hongwei, Dong Yangchao, Yao Min, Wang Yuan, Zhang Hui, Zhang Liang, Cheng Linfeng, Xu Zhikai, Lei Yingfeng, Zhang Fanglin, Ye Wei
机构信息
Department of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China.
Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
出版信息
Front Pharmacol. 2020 Feb 27;11:201. doi: 10.3389/fphar.2020.00201. eCollection 2020.
Abstract
[This corrects the article DOI: 10.3389/fphar.2019.01203.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fphar.2019.01203。]
相似文献
1
Corrigendum: An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection.勘误：一种改进的酶联聚焦形成试验揭示巴洛沙韦酸是一种抗汉坦病毒感染的潜在抗病毒治疗药物。
Front Pharmacol. 2020 Feb 27;11:201. doi: 10.3389/fphar.2020.00201. eCollection 2020.
2
An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection.一种改进的酶联聚焦形成试验表明，巴洛沙韦酸是一种针对汉坦病毒感染的潜在抗病毒治疗药物。
Front Pharmacol. 2019 Oct 16;10:1203. doi: 10.3389/fphar.2019.01203. eCollection 2019.
3
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.体外鉴定巴洛沙韦酸：一种新型流感病毒聚合酶 PA 亚单位依赖帽结构的内切核酸酶抑制剂。
Antiviral Res. 2018 Dec;160:109-117. doi: 10.1016/j.antiviral.2018.10.008. Epub 2018 Oct 11.
4
Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.2012-2018 年亚太地区流感病毒对巴洛沙韦的敏感性。
Antiviral Res. 2019 Apr;164:91-96. doi: 10.1016/j.antiviral.2019.02.007. Epub 2019 Feb 13.
5
Corrigendum: Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine With COVID-19 in Focus: A Nigerian Perspective.勘误：聚焦新冠疫情下非洲传统医学中抗病毒植物的治疗潜力：尼日利亚视角。
Front Pharmacol. 2021 Jul 20;12:721060. doi: 10.3389/fphar.2021.721060. eCollection 2021.
6
Corrigendum: Hantavirus: an overview and advancements in therapeutic approaches for infection.勘误：汉坦病毒：感染治疗方法的概述与进展
Front Microbiol. 2023 Dec 12;14:1343080. doi: 10.3389/fmicb.2023.1343080. eCollection 2023.
7
Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.在甲型流感病毒感染的小鼠模型中，使用帽依赖性内切酶抑制剂巴洛沙韦马波西利和神经氨酸酶抑制剂进行联合治疗。
J Antimicrob Chemother. 2019 Mar 1;74(3):654-662. doi: 10.1093/jac/dky462.
8
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.描述使用内切酶抑制剂巴洛沙韦治疗诱导的流感病毒变异体。
Sci Rep. 2018 Jun 25;8(1):9633. doi: 10.1038/s41598-018-27890-4.
9
Corrigendum: A Multi-Mode Bioactive Agent Isolated From L. Fill. With Therapeutic Potential for Type 2 Diabetes Mellitus.勘误：从L. Fill.中分离出的一种具有治疗2型糖尿病潜力的多模式生物活性剂。
Front Pharmacol. 2019 Jun 13;10:643. doi: 10.3389/fphar.2019.00643. eCollection 2019.
10
Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.流感病毒对新型帽依赖性内切酶抑制剂巴洛沙韦酯的敏感性。
Front Microbiol. 2018 Dec 6;9:3026. doi: 10.3389/fmicb.2018.03026. eCollection 2018.
Zotero 插件